金黃色葡萄球菌超抗原樣蛋白-5對(duì)內(nèi)皮祖細(xì)胞功能的影響
[Abstract]:In recent years, with the development of social economy and the aging of the population, atherosclerosis has become a serious threat to human health, which is the main cause of heart, brain and limb ischemia. The occurrence of atherosclerosis is associated with a variety of cardiovascular risk factors, and is based on atherosclerosis when known cardiovascular risk factors (smoking, blood lipids, blood pressure, blood sugar, etc.) are actively controlled. Cardiovascular and cerebrovascular diseases are still on the rise in China, which suggests that besides the common cardiovascular risk factors, some risk factors may not be taken seriously or controlled. Staphylococcus aureus, for example, is a common pathogen of cardiovascular system infections and is one of the common pathogens causing arterial lesions in patients with infective endocarditis and diabetic foot. It is beneficial to improve atherosclerosis and to clarify the role of certain infectious factors in vascular injury and repair. The level of prevention and treatment of complications.
Staphylococcal superantigen-like protein-5 (SSL5) is a secretory protein of Staphylococcus aureus (S. aureus). The purpose of this study is to further elucidate the role and mechanism of Staphylococcal infection in promoting angiopathy and thus preventing the blood vessels from infection. Lay the foundation for the occurrence of the disease.
Objective: To isolate and identify EPCs from human umbilical cord blood on the basis of constructing SSL5 protein expression vector, and to study the specific binding of SSL5 to PSGL-1 on the surface of EPCs, and the effects of SSL5 on the biological characteristics of EPCs such as adhesion, migration and proliferation.
Materials and Methods: (1) SSL5 protein expression vector was constructed, ssl5 gene was amplified from grape globe NCTC8325 strain, ssl5 gene was cloned into prokaryotic expression vector pET32a, and then transfected into E. coli BL21 for amplification and expression, and the purity of SSL5 protein was detected by SDS-PAGE electrophoresis; (2) density gradient centrifugation combined with adherent culture was used for isolation. Human umbilical cord blood-derived endothelial progenitor cells were cultured in the selective medium of endothelial cell line (EGM-2), and their surface markers were detected and identified by immunofluorescence. (3) The expression of PSGL-1 on the surface of EPCs was detected by confocal laser scanning and flow cytometry (FACS); the binding ability of SSL5 to EPCs was detected by FACS; and the anti-human PSGL-1 monoclonal antibody (KP) was detected by SSL5. The effects of different concentrations of SSL5 (0,1.0,3.0,10,30mg/L) on the adhesion, migration and proliferation of EPCs were studied by adhesion test, Millicell-PCF culture chamber and CK-8 kit.
Results: (1) The purity of recombinant SSL5 protein was detected by SDS-PAGE electrophoresis. (2) The isolated human umbilical cord blood-derived EPCs could differentiate into mature endothelial cells after 30 days of culture in endothelial selective medium, and expressed CD31. (3) Flow cytometry showed that PSGL-1 was present in EP. The results of confocal laser microscopy showed that PE-KPL-1 and FITC-UEA-1 double-stained positive cells accounted for 66.3% of the total cells. With the increase of SSL5 concentration, the binding of EPCs to PE-KPL-1 increased gradually. At the same time, SSL5 could competently inhibit the binding of KPL-1 and EPCs. SSL5 could also inhibit the binding of EPCs in P. - the adhesion of selectin surface can inhibit the migration and proliferation of EPCs.
Conclusion: (1) Human umbilical cord blood-derived EPCs have abundant PSGL-1 expression; (2) SSL5 can bind to PSGL-1 on the surface of EPCs and inhibit the adhesion of EPCs to P-selectin. This suggests that SSL5 may inhibit the adhesion of EPCs to the damaged endothelium by inhibiting the expression of E-/P-selectin and the migration and proliferation of EPCs. The repair function of EPCs decreased, and the formation of vascular disease was promoted.
【學(xué)位授予單位】:第三軍醫(yī)大學(xué)
【學(xué)位級(jí)別】:碩士
【學(xué)位授予年份】:2011
【分類號(hào)】:R392.1
【相似文獻(xiàn)】
相關(guān)期刊論文 前10條
1 張國馳;;超抗原刺激Th1細(xì)胞和Th2細(xì)胞誘生的細(xì)胞因子網(wǎng)絡(luò)[J];國外醫(yī)學(xué)(微生物學(xué)分冊(cè));1996年05期
2 侯彩霞;在不同的正常多特異性免疫球蛋白G制劑中其對(duì)鏈球菌超抗原的中和抗體的滴度不同:療效的推斷[J];國外醫(yī)學(xué).輸血及血液學(xué)分冊(cè);1999年01期
3 鄭翰;徐建國;;超抗原的研究進(jìn)展[J];中國人獸共患病學(xué)報(bào);2008年05期
4 郝林;韓從輝;;超抗原及靶向治療腫瘤作用進(jìn)展(英文)[J];現(xiàn)代生物醫(yī)學(xué)進(jìn)展;2009年19期
5 王藍(lán)田;世界上第一個(gè)超抗原抗癌生物制劑——高聚金葡素的臨床效果[J];中國腫瘤臨床;1998年05期
6 張國馳;;微生物超抗原可通過超抗原橋聯(lián)或獨(dú)立地經(jīng)細(xì)胞因子途徑激活T細(xì)胞[J];國外醫(yī)學(xué)(微生物學(xué)分冊(cè));1998年03期
7 林彤,孫建方;超抗原與特應(yīng)性皮炎[J];國外醫(yī)學(xué).皮膚性病學(xué)分冊(cè);2000年02期
8 鄭鎮(zhèn)西;超抗原及其應(yīng)用前景[J];微生物學(xué)免疫學(xué)進(jìn)展;2002年02期
9 陳鈺,張磊,鄧春江,周嚴(yán)恒,鐘大光,李紀(jì)選,劉穎;超抗原誘導(dǎo)活化的細(xì)胞是Th1而不是Th2[J];軍醫(yī)進(jìn)修學(xué)院學(xué)報(bào);1997年04期
10 岳峰;馬爾健;景懷琦;;假結(jié)核耶爾森菌超抗原的研究進(jìn)展[J];中國媒介生物學(xué)及控制雜志;2008年02期
相關(guān)會(huì)議論文 前10條
1 陳鵬;朱初麟;程江濤;杜廷海;;中醫(yī)藥對(duì)內(nèi)皮祖細(xì)胞的影響[A];第二屆全國中西醫(yī)結(jié)合心血管病中青年論壇暨第二屆黃河心血管病防治論壇資料匯編[C];2011年
2 周音頻;黃嵐;宋耀明;武曉靜;晉軍;張坡;宋明寶;;粒細(xì)胞集落刺激因子動(dòng)員骨髓促進(jìn)損傷血管內(nèi)皮修復(fù)[A];中國心臟大會(huì)(CHC)2011暨北京國際心血管病論壇論文集[C];2011年
3 蔡紹皙;陳斯佳;于文娟;;針刺,作為物理刺激對(duì)內(nèi)皮祖細(xì)胞的動(dòng)員作用[A];第十一次中國生物物理學(xué)術(shù)大會(huì)暨第九屆全國會(huì)員代表大會(huì)摘要集[C];2009年
4 李巍;王航;秦浙學(xué);劉潔;黃嵐;;硫化氫對(duì)大鼠骨髓源內(nèi)皮祖細(xì)胞數(shù)量及生理學(xué)特性影響[A];中國心臟大會(huì)(CHC)2011暨北京國際心血管病論壇論文集[C];2011年
5 張坡;黃嵐;朱鮮陽;韓秀敏;;辛伐他汀對(duì)大鼠平滑肌祖細(xì)胞和內(nèi)皮祖細(xì)胞遷移的不同影響[A];中國心臟大會(huì)(CHC)2011暨北京國際心血管病論壇論文集[C];2011年
6 趙剛;宋明寶;于學(xué)軍;朱光旭;于世勇;董紅梅;康華利;黃嵐;;肝細(xì)胞生長(zhǎng)因子對(duì)低密度脂蛋白損傷內(nèi)皮祖細(xì)胞功能的影響[A];第十三次全國心血管病學(xué)術(shù)會(huì)議論文集[C];2011年
7 張坡;黃嵐;朱鮮陽;韓秀敏;;辛伐他汀對(duì)大鼠平滑肌祖細(xì)胞和內(nèi)皮祖細(xì)胞遷移的不同影響[A];第十三次全國心血管病學(xué)術(shù)會(huì)議論文集[C];2011年
8 趙剛;宋明寶;于學(xué)軍;朱光旭;于世勇;董紅梅;康華利;黃嵐;;肝細(xì)胞生長(zhǎng)因子對(duì)低密度脂蛋白損傷內(nèi)皮祖細(xì)胞功能的影響[A];中國心臟大會(huì)(CHC)2011暨北京國際心血管病論壇論文集[C];2011年
9 李巍;王航;秦浙學(xué);劉潔;黃嵐;;硫化氫對(duì)大鼠骨髓源內(nèi)皮祖細(xì)胞數(shù)量及生理學(xué)特性影響[A];第十三次全國心血管病學(xué)術(shù)會(huì)議論文集[C];2011年
10 徐小勇;廉姜芳;葛世俊;周建慶;;大鼠骨髓內(nèi)皮祖細(xì)胞的中電導(dǎo)鈣離子激活鉀通道與容積敏感性氯離子通道[A];2011年浙江省心電生理與起搏學(xué)術(shù)年會(huì)論文匯編[C];2011年
相關(guān)重要報(bào)紙文章 前10條
1 徐述湘;揭開“超抗原”的抗癌奧秘[N];中國醫(yī)藥報(bào);2003年
2 廣文;超抗原理論與臨床實(shí)踐學(xué)術(shù)研討會(huì)在京落幕[N];醫(yī)藥經(jīng)濟(jì)報(bào);2002年
3 姜敏;協(xié)合集團(tuán)研制出超抗原生物新藥[N];經(jīng)濟(jì)參考報(bào);2005年
4 楊帆;沈陽協(xié)合在生物醫(yī)藥領(lǐng)域取得重大突破[N];科技日?qǐng)?bào);2007年
5 王廷兆;感冒誘發(fā)牛皮癬[N];醫(yī)藥經(jīng)濟(jì)報(bào);2004年
6 李明;感冒可誘發(fā)牛皮癬[N];中國醫(yī)藥報(bào);2004年
7 彭會(huì)安 王曉俏;自主創(chuàng)新耀神州[N];中國高新技術(shù)產(chǎn)業(yè)導(dǎo)報(bào);2006年
8 梁昕秋;協(xié)合集團(tuán)高科技產(chǎn)業(yè)化項(xiàng)目綜合評(píng)審達(dá)10.8億元[N];沈陽日?qǐng)?bào);2006年
9 廣聞;骨髓干細(xì)胞治療多種眼疾[N];醫(yī)藥經(jīng)濟(jì)報(bào);2002年
10 通訊員 王其玲 記者 羅堅(jiān)梅;干細(xì)胞,燃起人類絕處逢生新希望[N];杭州日?qǐng)?bào);2005年
相關(guān)博士學(xué)位論文 前10條
1 王s,
本文編號(hào):2182848
本文鏈接:http://sikaile.net/xiyixuelunwen/2182848.html